Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Burke Steven Keith

(Last) (First) (Middle)


(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/20/2019 P(1) 27,000 A $3.58(2) 37,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The purchase reported in this Form 4 was made on the open market.
2. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.50 to $3.64, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
/s/ Nicole R. Hadas, attorney-in-fact for Steven K. Burke 11/22/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

	Know all by these present, that the 
undersigned hereby constitutes and appoints 
each of John P. Butler, Jason A. Amello and Nicole R. 
Hadas signing singly, as the undersigneds true 
and lawful attorney-in-fact to:

(1)	prepare, execute in the undersigneds
 name and on the undersigneds behalf, and 
submit to the U.S. Securities and Exchange Commission (the SEC) 
a Form ID, including amendments thereto, and any other documents 
necessary or appropriate to obtain codes and passwords enabling 
the undersigned to make electronic filings with the SEC of reports 
required by Section 16(a) of the Securities Exchange Act of 1934, 
as amended (the Act) or any rule or regulation of the SEC;

	(2)	execute for and on behalf of the undersigned, in 
the undersigneds capacity as an officer, director and/or 
shareholder of Akebia Therapeutics, Inc. (the Company), 
Forms 3, 4 and 5 in accordance with Section 16(a) of the Act, 
and the rules thereunder;

	(3)	do and perform any and all acts for and on behalf 
of the undersigned that may be necessary or desirable to complete 
and execute any such Form 3, 4 or 5 and timely file such form with 
the SEC and any stock exchange or similar authority; and

	(4)	take any other action of any type whatsoever in 
connection with
 the foregoing that, in the opinion of such 
attorney-in-fact, may be of benefit to, in the best interest of, or 
legally required by, the undersigned, it being understood that the 
documents executed by such attorney-in-fact on behalf of the 
undersigned pursuant to this Power of Attorney shall be in such form 
and shall contain such terms and conditions as such attorney-in-fact 
may approve in such attorney-in-facts discretion.

	The undersigned hereby grants to each attorney-in-fact full 
power and authority to do and perform any and every act and thing 
whatsoever requisite, necessary or proper to be done in the exercise 
of any of the rights and powers herein granted, as fully to all intents 
and purposes as the undersigned might or could do if personally present, 
with full power of substitution or revocation, hereby ratifying and 
confirming all the acts such attorney-in-fact shall lawfully do or 
cause to be done by virtue of this Power of Attorney and the rights 
and powers herein granted.  The undersigned acknowledges that each of 
the foregoing attorneys-in-fact, in serving in such capacity at the 
request of the undersigned, is not assuming any of the undersigneds 
responsibilities to comply with Section 16 of the Act.

	This Power of Attorney shall remain in full force and effect 
until the undersigned is no longer required to file Forms 3, 4 and 5 
with respect to the undersigneds holdings of and transactions in 
securities issued by the Company, unless earlier revoked by the undersigned 
in a signed writing delivered to each of the foregoing attorneys-in-fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of 
Attorney to be executed as of July 31, 2019.

/s/ Steven K. Burke

 Steven K. Burke, M.D.